OMERS ADMINISTRATION Corp Makes New Investment in Personalis, Inc. (NASDAQ:PSNL)

OMERS ADMINISTRATION Corp bought a new stake in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 81,400 shares of the company's stock, valued at approximately $470,000. OMERS ADMINISTRATION Corp owned approximately 0.12% of Personalis as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its position in Personalis by 2,827.0% during the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock valued at $34,000 after purchasing an additional 5,654 shares in the last quarter. Olympiad Research LP purchased a new position in shares of Personalis in the fourth quarter valued at about $59,000. Alpine Global Management LLC purchased a new position in shares of Personalis in the fourth quarter valued at about $60,000. SG Americas Securities LLC purchased a new position in shares of Personalis in the fourth quarter valued at about $63,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Personalis in the fourth quarter valued at about $64,000. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis Price Performance

Shares of PSNL stock traded up $0.16 during trading hours on Friday, hitting $4.78. The stock had a trading volume of 484,344 shares, compared to its average volume of 1,015,974. Personalis, Inc. has a one year low of $1.14 and a one year high of $7.20. The stock's 50-day moving average price is $3.88 and its two-hundred day moving average price is $4.44. The stock has a market capitalization of $422.19 million, a price-to-earnings ratio of -2.85 and a beta of 1.83.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The firm had revenue of $20.61 million for the quarter, compared to analysts' expectations of $17.41 million. As a group, equities research analysts predict that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on PSNL. HC Wainwright boosted their price objective on Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, May 7th. Needham & Company LLC restated a "buy" rating and issued a $7.00 price objective on shares of Personalis in a research report on Thursday, April 10th. Guggenheim began coverage on Personalis in a research report on Thursday, May 15th. They issued a "buy" rating and a $6.00 price objective on the stock. Finally, Craig Hallum assumed coverage on Personalis in a research report on Monday, March 17th. They issued a "buy" rating and a $8.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Personalis presently has an average rating of "Buy" and a consensus price target of $7.67.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.